ArriVent BioPharma, Inc.
AVBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868279
No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Superinvestors holding AVBP, Q2 2026
1 superinvestor reports holding ArriVent BioPharma, Inc. on Form 13F, worth $136.5M in total. Weight is ArriVent BioPharma, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| HHLR Advisors (Hillhouse)Zhang Lei | 16.4% | 3,929,117 | $136.5M | Unchanged |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of AVBP each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q4 2025
1 superinvestor holding at quarter end
- Reduced
- HHLR Advisors (Hillhouse) (−12.4%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- HHLR Advisors (Hillhouse) (+14.1%)
Q1 2024
1 superinvestor holding at quarter end